X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
HF1K16 (ATRA liposome) is a novel small molecule RARβ2 agonist which is being evaluated in phase 1 clinical trials for the treatment of variety of refractory metastatic solid tumors such as gliomas and stomach, colorectal, liver, lung and ovarian cancers.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A. It is administered by infusion, travels through the blood stream and infiltrates the tumor microenvironment.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, it travels through the blood stream and infiltrates the tumor microenvironment. ATRA is released and initiate maturation of myeloid-derived suppressor cell.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of rosacea, in Canada.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SEARCHLIGHT PHARMA INC
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 06, 2023
Details:
HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, which targets myeloid-derived suppressor cells (MDSCs) in patients with refractory glioblastoma.
Lead Product(s): Tretinoin
Therapeutic Area: Oncology Product Name: HF1K16
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.
Lead Product(s): Arsenic Trioxide,Tretinoin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
TWYNEO combines, for the first time, two of the most commonly used topical agents available for the treatment of acne into a single application. TWYNEO is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
The combination therapeutic consists of biodegradable polymer nanospheres co-encapsulating a Bryoid and a Retinoid to improve synergistically alpha-secretase (α-secretase) production and reduce -amyloid plaque generation.
Lead Product(s): Bryostatin-1,Tretinoin
Therapeutic Area: Neurology Product Name: APH-1104
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
The fund will be directed towards the NDA filling of company's drug candidates- Epsolay and Twyneo.
Lead Product(s): Benzoyl Peroxide,Tretinoin
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: M. Arkin Dermatology Ltd
Deal Size: $28.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
